Tanshuhua

Dr.Tan’ laboratory uses interdisciplinary approaches including biochemistry, cell and molecular biology, bioinformatics and pharmacology to discover and design the innovative therapeutic biomolecules including peptides, proteins, antibodies, and nucleic acids with improved pharmacologic characteristics and/or product attributes based on the interactions between biological macromolecules for treating diabetes, cancers, hyperlipidemia, cardiovascular diseases, autoimmunity/inflammation, etc., as well as elucidate their underlying molecular mechanisms by exploring the details of receptor-mediated cell signaling events and the regulatory effects on of relevant genes at molecular, cellular and experimental animal levels.

1.Zhu Y., Ren S., Huang H., Wu J., You X., Gao J., Ren Y., Wang R., Zhao W., Tan S*.  Restoration of miR-299-3p promotes efferocytosis and ameliorates atherosclerosis via repressing CD47 in mice. FASEB J. 2024;38(15): e23857.

2.Zhang P., Wang K., Hu T., Xu M., You X., Chen M., Tang X., Hu H., Jiang Y., Zhao W., Tan S*.  A novel fully human anti-NT-ANGPTL3 antibody from phage display library exhibits potent ApoB, TG, and LDL-C lowering activities in hyperlipidemia mice. FASEB J. 2024;38(1): e23399.

3.Wang W., Chen X., Chen J., Xu M., Liu Y., Yang S., Zhao W., Tan S*.  Engineering lentivirus envelope VSV-G for liver targeted delivery of IDOL-shRNA to ameliorate hypercholesterolemia and atherosclerosis. Mol Ther Nucleic Acids. 2024;35(1): 102115.

4.Tong S., Zhu Y., Leng Y., Wu Y., Xiao X., Zhao W., Tan S*.  Restoration of miR-299-3p promotes macrophage phagocytosis and suppresses malignant phenotypes in breast cancer carcinogenesis via dual-targeting CD47 and ABCE1. Int Immunopharmacol. 2024;130: 111708.

5.Xu M., Zhang P., Lv W., Chen Y., Chen M., Leng Y., Hu T., Wang K., Zhao Y., Shen J., You X., Gu D., Zhao W., Tan S*.  A bifunctional anti-PCSK9 scFv/Exendin-4 fusion protein exhibits enhanced lipid-lowering effects via targeting multiple signaling pathways in HFD-fed mice. Int J Biol Macromol. 2023;253(Pt 4): 127003.

6.Xu M., Lei G., Chen M., Wang K., Lv W., Zhang P., Hu T., Gao J., Lu C., Mei Y., Xu Z., Bai Z., Hu H., Jiang Y., Tan S*.  Development of a novel, fully human, anti-PCSK9 antibody with potent hypolipidemic activity by utilizing phage display-based strategy. EBioMedicine. 2021;65: 103250.

7.Bai Z., Xu M., Mei Y., Hu T., Zhang P., Chen M., Lv W., Lu C., Tan S*.  Generation of a Novel High-Affinity Antibody Binding to PCSK9 Catalytic Domain with Slow Dissociation Rate by CDR-Grafting, Alanine Scanning and Saturated Site-Directed Mutagenesis for Favorably Treating Hypercholesterolemia. Biomedicines. 2021;9(12).

8.Xu Y., Gao J., Gong Y., Chen M., Chen J., Zhao W., Tan S*.  Hsa-miR-140-5p down-regulates LDL receptor and attenuates LDL-C uptake in human hepatocytes. Atherosclerosis. 2020;297: 111-119.

9.Gu L., Ye P., Li H., Wang Y., Xu Y., Tian Q., Lei G., Zhao C., Gao Z., Zhao W., Tan S*.  Lunasin attenuates oxidant-induced endothelial injury and inhibits atherosclerotic plaque progression in ApoE(-/-) mice by up-regulating heme oxygenase-1 via PI3K/Akt/Nrf2/ARE pathway. FASEB J. 2019;33(4): 4836-4850.

10.Lei G., Xu M., Xu Z., Lu C., Tan S*.  Combination of novel DR5 targeting agonistic scFv antibody TR2-3 with cisplatin shows enhanced synergistic antitumor activity in vitro and in vivo. Biomed Pharmacother. 2018;98: 271-279.

11.Tian Q., Zhang P., Gao Z., Li H., Bai Z., Tan S*.  Hirudin as a novel fusion tag for efficient production of lunasin in Escherichia coli. Prep Biochem Biotechnol. 2017;47(6): 619-626.

12.Lei G., Xu M., Xu Z., Gu L., Lu C., Bai Z., Wang Y., Zhang Y., Hu H., Jiang Y., Zhao W., Tan S*.  A Novel Fully Human Agonistic Single Chain Fragment Variable Antibody Targeting Death Receptor 5 with Potent Antitumor Activity In Vitro and In Vivo. Int J Mol Sci. 2017;18(10).

13.Zhu J., Zhou Q., Tan S*.  Targeting miRNAs associated with surface expression of death receptors to modulate TRAIL resistance in breast cancer. Cancer Lett. 2016;383(2): 154-160.

14.Dai G., Zhang P., Ye P., Zhang M., Han N., Shuai H., Tan S*.  The Chemopreventive Peptide Lunasin Inhibits d-Galactose- Induced Experimental Cataract in Rats. Protein Pept Lett. 2016;23(7): 619-625.

15.Setrerrahmane S., Zhang Y., Dai G., Lv J., Tan S*.  Efficient production of native lunasin with correct N-terminal processing by using the pH-induced self-cleavable Ssp DnaB mini-intein system in Escherichia coli. Appl Biochem Biotechnol. 2014;174(2): 612-622.